Summary

Global Inflammatory Bowel Disease Treatment Market is valued approximately USD 19.2 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4.8 % over the forecast period 2021-2027. The term Inflammatory Bowel Disease is used for mainly two conditions Crohn's disease and ulcerative colitis. Increase in prevalence of Crohn's disease and ulcerative colitis is the key factor driving the market of inflammatory bowel disease treatment. According to the Crohn’s and Colitis Foundation (CCFA), approximately 70,000 fresh cases of inflammatory bowel disease are investigated in the U.S. every year. As per the CCFA report of 2019, about 1.6 million cases were diagnosed in U.S with Inflammatory Bowel Disease. In Europe there were approximately 3.4 billion people were found with any form of IBD in 2020, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA). Growing population of affected people are rising the demand for effective treatment options. Increasing permissions for biosimilars such as Hyrimoz, Imraldi, Renflexis, and Inflectra is projected to increase the adoption of effective treatment due to its advantages over traditional treatment methods. However, high cost of treatment is predicted to impede the growth of the market over the forecast period of 2021-2027. Also, increasing geriatric population is likely to increase the market growth during the forecast period.

The regional analysis of global Inflammatory Bowel Disease Treatment Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the dominating region across the world in terms of market share owing to increasing treatment rates, growing prescription of novel drugs, and better reimbursement policies are some factors affecting the market growth in the region. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as growing Crohn’s disease and ulcerative colitis in the region, increasing prescription of biosimilars, and rising novel drug approval would create lucrative growth prospects for the Inflammatory Bowel Disease Treatment Market across Asia-Pacific region.

Major market player included in this report are:
AbbVie Inc.
Biogen
Johnson & Johnson Services, Inc.
Amgen Inc.
UCB S.A.
Novartis AG
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Pfizer Inc.
Lilly

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Crohn's Disease
Ulcerative Colitis

By Drug Class:
Aminosalicylates
Corticosteroids
TNF inhibitors
IL inhibitors
Anti-integrin
JAK inhibitors
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy



By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Inflammatory Bowel Disease Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Inflammatory Bowel Disease Treatment Market, by Region, 2019-2027 (USD Billion)
1.2.2. Inflammatory Bowel Disease Treatment Market, by Type, 2019-2027 (USD Billion)
1.2.3. Inflammatory Bowel Disease Treatment Market, by Drug Class, 2019-2027 (USD Billion)
1.2.4. Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2019-2027 (USD Billion)
1.2.5. Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Inflammatory Bowel Disease Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Inflammatory Bowel Disease Treatment Market Dynamics
3.1. Inflammatory Bowel Disease Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of Crohn’s disease and ulcerative colitis
3.1.1.2. Robust product pipeline
3.1.1.3. Emergence of biosimilars
3.1.2. Market Challenges
3.1.2.1. High cost of treatment
3.1.3. Market Opportunities
3.1.3.1. Increasing geriatric population
Chapter 4. Global Inflammatory Bowel Disease Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Inflammatory Bowel Disease Treatment Market, by Type:
5.1. Market Snapshot
5.2. Global Inflammatory Bowel Disease Treatment Market by Type, Performance - Potential Analysis
5.3. Global Inflammatory Bowel Disease Treatment Market Estimates & Forecasts by Type 2018-2027 (USD Billion)
5.4. Inflammatory Bowel Disease Treatment Market, Sub Segment Analysis
5.4.1. Crohn’s disease
5.4.2. Ulcerative colitis
Chapter 6. Global Inflammatory Bowel Disease Treatment Market, by Drug Class:
6.1. Market Snapshot
6.2. Global Inflammatory Bowel Disease Treatment Market by Drug Class, Performance - Potential Analysis
6.3. Global Inflammatory Bowel Disease Treatment Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)
6.4. Inflammatory Bowel Disease Treatment Market, Sub Segment Analysis
6.4.1. Aminosalicylates
6.4.2. Corticosteroids
6.4.3. TNF inhibitors
6.4.4. IL inhibitors
6.4.5. Anti-integrin
6.4.6. JAK inhibitors
6.4.7. Others


Chapter 7. Global Inflammatory Bowel Disease Treatment Market, by Route of Administration
7.1. Market Snapshot
7.2. Global Inflammatory Bowel Disease Treatment Market by Route of Administration, Performance - Potential Analysis
7.3. Global Inflammatory Bowel Disease Treatment Market Estimates & Forecasts by Route of Administration 2018-2027 (USD Billion)
7.4. Inflammatory Bowel Disease Treatment Market, Sub Segment Analysis
7.4.1. Oral
7.4.2. Injectable
Chapter 8. Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Inflammatory Bowel Disease Treatment Market by Distribution Channel, Performance - Potential Analysis
8.3. Global Inflammatory Bowel Disease Treatment Market Estimates & Forecasts by Distribution Channel 2018-2027 (USD Billion)
8.4. Inflammatory Bowel Disease Treatment Market, Sub Segment Analysis
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.4.3. Online Pharmacy

Chapter 9. Global Inflammatory Bowel Disease Treatment Market, Regional Analysis
9.1. Inflammatory Bowel Disease Treatment Market, Regional Market Snapshot
9.2. North America Inflammatory Bowel Disease Treatment Market
9.2.1. U.S. Inflammatory Bowel Disease Treatment Market
9.2.1.1. Type breakdown estimates & forecasts, 2018-2027
9.2.1.2. Drug class breakdown estimates & forecasts, 2018-2027
9.2.1.3. Route of Administration breakdown estimates & forecasts, 2018-2027
9.2.1.4. Distribution Channel breakdown estimates & forecasts, 2018-2027

9.2.2. Canada Inflammatory Bowel Disease Treatment Market
9.3. Europe Inflammatory Bowel Disease Treatment Market Snapshot
9.3.1. U.K. Inflammatory Bowel Disease Treatment Market
9.3.2. Germany Inflammatory Bowel Disease Treatment Market
9.3.3. France Inflammatory Bowel Disease Treatment Market
9.3.4. Spain Inflammatory Bowel Disease Treatment Market
9.3.5. Italy Inflammatory Bowel Disease Treatment Market
9.3.6. Rest of Europe Inflammatory Bowel Disease Treatment Market
9.4. Asia-Pacific Inflammatory Bowel Disease Treatment Market Snapshot
9.4.1. China Inflammatory Bowel Disease Treatment Market
9.4.2. India Inflammatory Bowel Disease Treatment Market
9.4.3. Japan Inflammatory Bowel Disease Treatment Market
9.4.4. Australia Inflammatory Bowel Disease Treatment Market
9.4.5. South Korea Inflammatory Bowel Disease Treatment Market
9.4.6. Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market
9.5. Latin America Inflammatory Bowel Disease Treatment Market Snapshot
9.5.1. Brazil Inflammatory Bowel Disease Treatment Market
9.5.2. Mexico Inflammatory Bowel Disease Treatment Market
9.6. Rest of The World Inflammatory Bowel Disease Treatment Market

Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. AbbVie Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Biogen
10.2.3. Johnson & Johnson Services, Inc.
10.2.4. Amgen Inc.
10.2.5. UCB S.A.
10.2.6. Novartis AG
10.2.7. Takeda Pharmaceutical Company Limited
10.2.8. Merck & Co., Inc.
10.2.9. Pfizer Inc.
10.2.10. Lilly
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption